Robert Pascuzzi, MD
Neurology · Indianapolis, INNPI 1710901277
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by UCB SA at 59.1% of the total. Reporting peaked in 2019 at $1,001 and has fallen 56.9% since, to $432 in 2025. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 14 payments — averaging $120.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1K
- UCB, Inc.$347
- Argenx US, Inc.$260
- AstraZeneca$84
Across 45 payments — averaging $12,906 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$535K
- AstraZeneca$20K
- Grifols Therapeutics LLC$20K
- Apellis Pharmaceuticals, Inc.$6K
What the payments were for
- Travel & lodging$89653%
- Food & beverage$79747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 7 | $1,001 |
| UCB, Inc. | 3 | $347 |
| Argenx US, Inc. | 3 | $260 |
| AstraZeneca | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$103
How this compares
$1,693 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ChenodalChenodiol | 12 | $1,230,564 |
| SkyclarysOmaveloxolone | 33 | $1,075,328 |
| FirdapseAmifampridine Phosphate | 23 | $1,066,584 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 55 | $637,187 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 40 | $618,089 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $461,146 |
| EvrysdiRisdiplam | 13 | $341,954 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $115,951 |
| Emgality PenGalcanezumab-Gnlm | 30 | $22,950 |
| Nurtec OdtRimegepant Sulfate | 18 | $22,323 |
| UbrelvyUbrogepant | 18 | $19,333 |
| Pyridostigmine Bromide | 128 | $16,912 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $10,855 |
| Mycophenolate Mofetil | 34 | $6,549 |
| Divalproex Sodium ErDivalproex Sodium | 59 | $4,511 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Cassandra CurtisIndianapolis$181K
- Martin FarlowIndianapolis$148K
- Eric SiemersIndianapolis$101K
- Liana ApostolovaIndianapolis$95K
- Jared BroschIndianapolis$68K
- Kaustubh LimayeIndianapolis$44K
- Michael SermersheimIndianapolis$32K
- Cynthia McGarveyIndianapolis$27K
- David GlanderIndianapolis$25K
- Leo DambrosioIndianapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.